Czech/SlovakiaCzech RepublicSlovakia

AbCheck pockets pharma deal

03.11.2010

Plzen – Czech antibody discovery and development specialist AbCheck s.r.o. has signed its first contract with a big pharma company. In October, the yearling Czech spin-off from German antibody drug developer Affimed GmbH announced an anti­body discovery deal with Eli Lilly and Company. Under the terms of the agreement, AbCheck will use its three antibody discovery libraries, which are comprised of 10 billion structurally diverse proteins, to deliver fully human antibodies against diverse IgM, semi-synthetic and fully synthetic library display antibodies as scFv on the surface of phage particles. Lilly will receive all rights concerning the antibodies from AbCheck, which in return will receive discovery fees and development milestones totalling an undisclosed amount, according to the contract negotiated with IP consultants from Freshfields Bruckhaus Deringer. The Plzen-based antibody service company took over IP antibody discovery processes – from early stage research to lead optimisation – from Affimed, which is focussed on developing its pipeline of preclinical tetra­valent monoclonal antibody drugs.

Czech/SlovakiaCzech RepublicSlovakia

07.03.2012

The Czech government has beefed up its investments in biotech with the help of EU structural funds. In February, the country’s Education Minister Josef Dobes gave the go-ahead for the Biocev centre in Vestec near Prague. Although...

Czech/SlovakiaCzech RepublicSlovakia

05.12.2011

Brno – Czech Prime Minister Petr Necas has officially inaugurated the first of six European Technology Institutes slated to be launched in the Czech Republic with help from European FEDER funds. Although construction of the €200m...

Czech/SlovakiaCzech RepublicSlovakia

01.10.2011

Prague – Czech drug developer VUAB Pharma a.s. has joined CzechBio. The company, which has its headquarters in Roztoky near Prague, became the 35th member of the Czech biotechnology industry association in September. VUAB...

Czech/SlovakiaCzech RepublicSlovakia

09.08.2011

Praque – A team of researchers headed by Dr. Valdimir Kral, Director of Chemical Development at Sanofi-Aventis’ Czech research unit Zentiva Development sro, has presented a new targeted drug delivery system that couples combined...

Czech/SlovakiaCzech RepublicSlovakia

01.06.2011

Brno – Plans for building a Central European Insitute of Technology (CEITEC) in Brno look set to take a big step closer to becoming reality. In mid-May, CEITEC representatives announced that EU financing for the EUR260m...

Czech/SlovakiaCzech RepublicSlovakia

13.09.2010

Prague – CzechInvest has called on Czech high-tech companies in the field of ICT, bio­technology, clean technology and micro­electronics to apply for the Czech Technology Accelerator programme. Under the third call, which was...

Czech/SlovakiaCzech RepublicSlovakia

02.07.2010

Prague – Czech researchers from Charles University in Prague have discovered a molecular biomarker that helps to predict toxicity and a higher risk for adverse effects in children with juvenile arthritis that are treated with...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Prague – Czech biotech company Lenti­Kats AS has begun worldwide commercialisation of a patented, cost-effective encapsulation technology for use in the food and bio­pharmaceuticals industry. The company has discovered a way to...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Sofia – Bulgaria’s parliament has approved a law that will in effect ban any cultivation of GMO crops in the country. “There will be no field on the country’s territory where GMOs can be cultivated,” said Kostadin Yazov from the...

Displaying results 1 to 10 out of 70

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-czech-slovakia/article/abcheck-pockets-pharma-deal.html

Events

All Events

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR303.8%
  • SANTHERA (CH)68.90 CHF102.6%
  • ADDEX (CH)4.06 CHF82.1%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-29.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)68.90 CHF3433.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP769.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)9.69 EUR-69.2%

No liability assumed, Date: 23.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products